Skip to main content

Nasus Pharma Ltd

corporate_fare Company Profile

Nasus Pharma Ltd

NSRX·NYSE·Life Sciences·CIK 0002029039

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs to treat emergency medical conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since the nose is lined with a very rich vascular bed enabling quick drug absorption. The company is developing a proprietary PBI technology with a specialized product portfolio to address acute medical conditions and public health threats. Nasus Pharma believes PBI may be superior to liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, creating a larger absorption area and enabling more rapid and higher drug absorption. In addition, the uniform spherical powder particles of its proprietary formulation may enhance the consistency and reliability of the delivered dose. Initial clinical trials of PBI products involving different molecules have demonstrated quicker and higher drug absorption over similar solution-based nasal products; however, to date the company has only tested its product candidates on a relatively small patient population and none of its products have been approved by the FDA. Additional clinical testing will be required before FDA approval of any product candidate. The company is focused on developing NS002, an Intranasal Epinephrine, and has also been developing NS001, an Intranasal Naloxone, which it has paused, planning to pursue partnering opportunities for further development of NS001. Nasus Pharma currently has no FDA-approved products.

Nasus Pharma Ltd (NYSE:NSRX) is a publicly traded company in the Life Sciences sector.

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$5.86M
Diluted EPS
-$0.72
Op. Cash Flow
-$4.92M
Free Cash Flow
-$4.93M
Operating Income
-$4.9M
Cash & Equivalents
$1.24M
Debt / Equity
0.00×
Shares Outstanding
9.02M sh
Source: 20-F · filed 2026-03-25 · accession 0001493152-26-012559

Short Interest & Short Volume

3.65 days to cover

FINRA reported short interest of 71,005 shares in NSRX as of the October 30, 2026 settlement, a 11.7% decrease from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 58.3% of NSRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)71,005 shares as of October 30, 2026
Change vs prior period▼ 11.7%
Days to cover3.65 at avg daily volume of 19,443
Daily short volume (FINRA facilities)58.3% of 18,336 shares on November 20, 2026
5-day average short volume51.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

NSRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$2.25 -1.75% today
Market cap
$26.82M
Volume
34K (2.0× avg)
3-mo avg 16.6K
Live data · 2026-11-21 15:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NSRX - Latest Insights

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets